Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Gemifloxacin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 1.00 |
| ▸ | ABCC4 | O15439 | 1/20 | 1.00 |
| ▸ | DPP4 | P27487 | 6/20 | 0.93 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.93 |
| ▸ | DRD1 | P21728 | 1/20 | 0.93 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | XBP1 | P17861 | 1/20 | 0.47 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.47 |
| ▸ | RELA | Q04206 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | DHFR | P00374 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | ATP6V1B2 | P21281 | 1/20 | 0.40 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Gemifloxacin SCHEMBL136827 | 1.00 | LMNA (1.00) | LMNAKDM4EHSD17B10ABCC4DPP4 | |
| Gemifloxacin SCHEMBL2421086 | 1.00 | LMNA (1.00) | LMNAKDM4EHSD17B10ABCC4DPP4 | |
| Gemifloxacin SCHEMBL3141327 | 1.00 | LMNA (1.00) | LMNAKDM4EHSD17B10ABCC4DPP4 | |
| Gemifloxacin SCHEMBL29408809 | 1.00 | LMNA (1.00) | LMNAKDM4EHSD17B10ABCC4DPP4 | |
| Gemifloxacin SCHEMBL2421087 | 1.00 | LMNA (1.00) | LMNAKDM4EHSD17B10ABCC4DPP4 | |
| Gemifloxacin SCHEMBL5661711 | 0.99 | LMNA (0.98) | LMNAKDM4EHSD17B10ABCC4DPP4 | |
| Gemifloxacin SCHEMBL5661708 | 0.99 | LMNA (0.98) | LMNAKDM4EHSD17B10ABCC4DPP4 | |
| Gemifloxacin SCHEMBL3281156 | 0.99 | LMNA (0.98) | LMNAKDM4EHSD17B10ABCC4DPP4 | |
| Gemifloxacin SCHEMBL3281159 | 0.99 | LMNA (0.98) | LMNAKDM4EHSD17B10ABCC4DPP4 | |
| Gemifloxacin SCHEMBL5658681 | 0.99 | LMNA (0.98) | LMNAKDM4EHSD17B10ABCC4DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 300 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118878838-A | Preparation method and application of metal organic framework material for adsorbing quinolone medicines | 新疆畜牧科学院畜牧业质量标准研究所（新疆维吾尔自治区种羊与羊毛羊绒质量安全监督检验中心） | 2024-11-01 | — | — | CN | claimed |
| CN-114814013-B | Method for rapidly screening unknown chemical hazard residues in aquatic products based on high-resolution mass spectrum database | 中国海洋大学 | 2023-06-02 | — | — | CN | claimed |
| EP-4057813-A1 | COMPOSITIONS AND METHODS FOR TREATING HUANGLONGBING DISEASE IN CITRUS | New Life Crop Sciences LLC (US) | 2022-09-21 | — | — | EP | claimed |
| CN-114980736-A | Compositions and methods for treating citrus greening disease | 新生命作物科学有限责任公司 | 2022-08-30 | — | — | CN | claimed |
| WO-2021133279-A1 | A SOLID ORAL PHARMACEUTICAL GEMIFLOXACIN MESYLATE COMPOSITION WITH IMPROVED RELEASE PATTERN AND DISINTEGRATION MECHANISM | SANTA FARMA İLAÇ SANAYİ A.Ş. (TR) | 2021-07-01 | — | — | WO | claimed |
| WO-2021097410-A1 | COMPOSITIONS AND METHODS FOR TREATING HUANGLONGBING DISEASE IN CITRUS | NEW LIFE CROP SCIENCES LLC (US) | 2021-05-20 | — | — | WO | claimed |
| US-20210144998-A1 | COMPOSITIONS AND METHODS FOR TREATING HUANGLONGBING DISEASE IN CITRUS | NEW LIFE CROP SCIENCES LLC | 2021-05-20 | — | — | US | claimed |
| CN-112362783-A | High-flux and rapid screening method for potential pollutants in non-medicines for fishing | 江苏省淡水水产研究所 | 2021-02-12 | — | — | CN | claimed |
| US-20200095627-A1 | MOLECULAR SENSORS AND USES THEREOF | NEW YORK UNIVERSITY | 2020-03-26 | — | — | US | claimed |
| US-20190133924-A1 | Alcohol-Resistant Formulations | CIMA LABS INC (US) | 2019-05-09 | — | — | US | claimed |
| WO-2003045389-A1 | A METHOD OF TREATING BACTERIAL INFECTIONS USING GEMIFLOXACIN OR A SALT THEREOF AND A CARBAPENEM ANTIBACTERIAL AGENT | LG LIFE SCIENCES LTD. (KR) | 2003-06-05 | — | — | WO | claimed |
| US-20030078272-A1 | Methods of use of fluoroquinolone compounds against ciprofloxacin-resistant and ciprofloxacin-sensitive pathogenic bacteria | SMITHKLINE BEECHAM CORPORATION | 2003-04-24 | — | — | US | claimed |
| US-20020137751-A1 | Method of treatment | LG LIFE SCIENCES LIMITED (KR) | 2002-09-26 | — | — | US | claimed |
| US-6455540-B1 | USING GEMIFLOXACIN COMPOUND | SMITHKLINE BEECHAM CORPORATION | 2002-09-24 | — | — | US | claimed |
| EP-1223935-A1 | METHODS OF USE OF FLUOROQUINOLONE COMPOUNDS AGAINST BACTERIA | SmithKline Beecham Corporation (US) | 2002-07-24 | — | — | EP | claimed |
| WO-2002038156-A2 | METHODS OF USE OF FLUOROQUINOLONE COMPOUNDS AGAINST PATHOGENIC HELICOBACTER BACTERIA | SMITHKLINE BEECHAM CORPORATION (US) | 2002-05-16 | — | — | WO | claimed |
| US-6340689-B1 | CONTACTING ATYPICAL UPPER RESPIRATORY PATHOGENIC BACTERIA, ESPECIALLY LEGIONELLA SPECIES, WITH ANTIBACTERIALLY EFFECTIVE AMOUNT OF COMPOSITION COMPRISING GEMIFLOXACIN COMPOUND OR ANTIBACTERIALLY EFFECTIVE DERIVATIVE THEREOF | SMITHKLINE BEECHAM CORPORATION | 2002-01-22 | — | — | US | claimed |
| US-6331550-B1 | MODULATING METABOLISM OF ANAEROBIC PATHOGENIC BACTERIA BY CONTACTING BACTERIA WITH ANTIBACTERIALLY EFFECTIVE AMOUNT OF COMPOSITION COMPRISING GEMIFLOXACIN COMPOUND OR DERIVATIVE | SMITHKLINE BEECHAM CORPORATION | 2001-12-18 | — | — | US | claimed |
| US-6262071-B1 | ADMINISTERING A GEMIFLOXACIN COMPOUND, OR ANTIBACTERIALLY EFFECTIVE DERIVATIVES THEREOF. | SMITHKLINE BEECHAM CORPORATION | 2001-07-17 | — | — | US | claimed |
| WO-2001000209-A1 | METHODS OF USE OF FLUOROQUINOLONE COMPOUNDS AGAINST BACTERIA | SMITHKLINE BEECHAM CORPORATION (US) | 2001-01-04 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030078272-A1 | Methods of use of fluoroquinolone compounds against ciprofloxacin-resistant and ciprofloxacin-sensitive pathogenic bacteria | DDX5, DHX35, TOP2A | LMNA 1591/4885KDM4E 2564/4885HSD17B10 1941/4885 |
| US-20210144998-A1 | COMPOSITIONS AND METHODS FOR TREATING HUANGLONGBING DISEASE IN CITRUS | PNPO, G6PD, AGXT | LMNA 1773/4885KDM4E 2866/4885HSD17B10 1061/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.